Compare Merck & Co., Inc. (MRK) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Ryanair Holdings plc — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while Ryanair Holdings plc trades at $59.4 (market cap $29.63B). The key difference: Merck & Co., Inc. is far larger — about 10.9× Ryanair Holdings plc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | RYAAY | |
|---|---|---|
Market Cap | $321.77B | $29.63B |
Sector | Health | Industrials |
52-Week High | $131.84 | $73.82 |
52-Week Low | $77.60 | $53.24 |
Enterprise Value | $368.53B | $26.61B |
Dividend Yield | 2.61% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
RYAAY trades at $59.36, down 0.25% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and attractive valuation with a P/E of 14.37. Recent news highlights a strategic AI partnership with Google Cloud and industry challenges from lower fares and fuel costs.
The outlook is balanced; analyst consensus is bullish (62.5% buy ratings), but near-term headwinds from fare pressure and geopolitical risks persist. The stock offers value based on earnings, though operational volatility and competitive dynamics require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
